Location Philadelphia, Pennsylvania, United States Regions Greater Philadelphia Area, Great Lakes, Northeastern US Gender Male
LinkedIn View on LinkedIn
Greg has been developing targeted cancer therapeutics for over 30 years. Most recently Greg was the Chief Scientific Officer of Sesen Bio, previously known as Eleven Biotherapeutics/Viventia Biotech, a publicly traded, late clinical-stage biotech company developing targeted protein therapeutics for the treatment of non-muscle invasive bladder
cancer. In addition to leading Sesen’s early development pipeline, Greg was part of the fundraising team that raised over 60 million dollars to support Sesen’s research and clinical programs. Prior to joining Viventia Biotech Greg was a member of the faculty of Fox Chase Cancer Center in Philadelphia and a Co-leader of the Developmental Therapeutics Program. At Fox Chase Greg lead a laboratory program focused on developing antibody-based treatments for cancer.
Greg received a Ph.D. in Immunology from the University of California, Davis and a bachelor’s degree in Biology from the University of California, Santa Cruz. Greg is a member of the editorial boards of Cancer Immunology Research, Cancer Biotherapy and Radiopharmaceuticals and MAbs and has served as a member the Department of Defense Breast Cancer Research Program Integration Panel, numerous National Cancer Institute and DoD peer-review panels and the Scientific Advisory Boards of numerous companies including Mersana, Symphogen, Endo Oncology, Viventia Bio and Integral Molecular.
